- 503Pharma
- Posts
- Group Lab Testing Program Is Almost Here — Are You In?
Group Lab Testing Program Is Almost Here — Are You In?
We need a headcount before we finalize pricing with our lab partners.
503Pharma .
June 08, 2026
What's Next After GLP-1? Now 100+ Formulas to Build a Resilient Formulary
Sterile and non-sterile, built to current USP 795/797 standards with BUD assignments included. Recent additions include Wolverine blend, KPV, DSIP, PT-141 nasal spray, and many more.
100+ formulations across sterile and non-sterile categories
BUD assignments aligned to USP 795 and 797
Custom formulation requests
Regularly updated as FDA and USP guidance evolves
The members area is free to join. Formula access is a paid feature.
A few months ago, we announced that 503Pharma would be building a group purchasing program for lab testing. The response confirmed the demand, so we've been executing on it.
We're now close to finalizing our contract lab partners. Before we lock in pricing, we need to know how many pharmacies are in — your volume is our leverage.
The timing matters. The PCAC meets July 23–24 to review seven peptides — including BPC-157, TB-500, KPV, and MOTS-C — for potential inclusion on the 503A bulks list. Some of these peptides will move to Category 1, and pharmacies that have stability data will have a massive advantage!
The program covers:
Stability studies (USP <797> BUDs) — easily $15K–$30K+ per study when you're buying alone
Release / potency testing
Sterility testing
Bacterial endotoxin (BET)
No commitment yet. Just raise your hand so we can negotiate with real numbers.
Reply with "I'M IN" and we'll loop you into next steps.
✉️ That’s your 503Pharma weekly digest. Our mission is to keep compounding professionals informed, prepared, and ahead of the curve.